TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05335070
Drug: Temporo-masseteric Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
Study: NCT05507541
Drug: Ontorpacept
Normalized name: Ontorpacept
DrugBank: Ontorpacept (DB17116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05507541
Drug: Maplirpacept
Normalized name: Maplirpacept
DrugBank: Maplirpacept (DB18441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05620901
Drug: Pred Forte
Normalized name: Pred Forte
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To treat perioperative ocular inflammation and pain;
Study: NCT04501614
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib tablets.
Study: NCT06483100
Drug: Elrantamab
Normalized name: elranatamab
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15
Study: NCT06283589
Drug: INZ-701
Normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Study: NCT05009069
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Study: NCT05009069
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Study: NCT04697511
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
Study: NCT04697511
Drug: M2951
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
Study: NCT06393868
Drug: Omeprazole 20 mg Oral Tablet
Normalized name: omeprazole 20 MG Oral Tablet
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole once daily for 90 days
Study: NCT00050271
Drug: Acetyl-L-carnitine
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05183035
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05183035
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT05183035
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05183035
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion or subcutaneous injection
Study: NCT05183035
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally via tablet or powder suspension
Study: NCT05896293
Drug: kisspeptin 112-121
Normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
Study: NCT05896293
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC bolus
Study: NCT05482542
Drug: Cyclophosphamide/Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cyclophosphamide/Rituximab
Study: NCT04640025
Drug: itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
Study: NCT05509777
Drug: Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC
Study: NCT04951622
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab will be administered as an IV infusion.
Study: NCT04666038
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Pirtobrutinib
Study: NCT04666038
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT04666038
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT04666038
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT06054776
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05166577
Drug: Nanatinostat
Normalized name: Nanatinostat
DrugBank: Nanatinostat (DB15419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b: Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week, then Phase 2: Nanatinostat at the confirmed recommended Phase 2 dose
Study: NCT05166577
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1b: Valganciclovir starting at 900 mg orally daily, then Phase 2: Valganciclovir at the confirmed recommended Phase 2 dose
Study: NCT05166577
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 2: Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
Study: NCT06437080
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
Study: NCT06572813
Drug: Bortezomib Injection
Normalized name: bortezomib Injection
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib Injection, a kind of chemotherapy drug
Study: NCT06572813
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody
Study: NCT04686305
Drug: T-DXd
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DXd: administered as an IV infusion
Study: NCT04686305
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin: administered as an IV infusion
Study: NCT04686305
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin: administered as an IV infusion
Study: NCT04686305
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed: administered as an IV infusion (drug not used)
Study: NCT04686305
Drug: Volrustomig
Normalized name: Volrustomig
DrugBank: Volrustomig (DB18893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volrustomig: administered as an IV infusion
Study: NCT04889183
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
Study: NCT04686305
Drug: Rilvegostomig
Normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilvegostomig: administered as an IV infusion
Study: NCT06350773
Drug: tadalafil 20 mg then 40 mg if tolerated
Normalized name: tadalafil 40 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
Study: NCT05067790
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as specified in the treatment arm
Study: NCT06219317
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab is provided in a 10 ml glass vial
Study: NCT03941860
Drug: Ixazomib Citrate
Normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03941860
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06133972
Drug: Ianalumab
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ianalumab s.c. monthly Ianalumab s.c. quarterly
Study: NCT06497075
Drug: Albendazole 400mg
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of Albendazole 400mg tablet
Study: NCT06497075
Drug: Ivermectin 3 MG
Normalized name: ivermectin 3 MG
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)
Study: NCT05107427
Drug: MRx0518
Normalized name: MRx0518
DrugBank: MRx0518 (DB17523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
Study: NCT05761041
Drug: Sodium Fluoride Varnish (5%)
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied at baseline
Study: NCT05761041
Drug: SDF
Normalized name: WinRho SDF
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied bianually
Study: NCT05132504
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.
Study: NCT05775406
Drug: KT-253
Normalized name: KT-253
DrugBank: KT-253 (DB18487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT-253 will be administered intravenously per the defined protocol frequency and dose level.
Study: NCT05526391
Drug: TAK-341
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-341 IV infusion
Study: NCT05175027
Drug: hypochlorous acid
Normalized name: Hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomize
Study: NCT05385952
Drug: TachoSil
Normalized name: TachoSil
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.
Study: NCT06544993
Drug: Meso-botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Micro-Botox, is a highly diluted Botulinum toxin type A
Study: NCT06417554
Drug: SHR-A2102
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A2102
Study: NCT06417554
Drug: SHR-A2102 ; Adebrelimab injection
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A2102 + Adebrelimab injection
Study: NCT05194293
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05035407
Drug: IL-2 (Aldesleukin)
Normalized name: Ile
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period beginning within 24 hours of cell infusion and continuing for up to four days (maximum 12 doses).
Study: NCT05035407
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2 IV infusion over 30 minutes (+ 10 min) To be administered following completion of cyclophosphamide. Once daily x 5 doses (Days -6, -5, -4, -3, -2)
Study: NCT05308264
Drug: R906289 Monosodium (R289 Na)
Normalized name: Monosodium Glutamate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd,500 mg PO qd, 750 mg PO qd, 1000 mg PO qd)
Study: NCT04710641
Drug: MTL-CEBPA
Normalized name: MTL-CEBPA
DrugBank: MTL-CEBPA (DB18143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once every 3 weeks on Day 1 of each 3 week cycle.
Study: NCT04710641
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral adminstration twice a day
Study: NCT05704543
Drug: Buprenorphine Extended-Release Injection
Normalized name: Buprenorphine Extended-Release Injection
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as a subcutaneous injection.
Study: NCT05037500
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06532032
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered as IV infusion.
Study: NCT06532032
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered as IV infusion.
Study: NCT06745297
Drug: BI 3776528
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 3776528
Study: NCT05757336
Drug: Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
Study: NCT05551767
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
Study: NCT06279728
Drug: Datopotamab deruxtecan
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)
Study: NCT05928728
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5 mg once daily
Study: NCT06534671
Drug: diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.
Study: NCT05407597
Drug: Icatibant
Normalized name: Icatibant
DrugBank: Icatibant (DB06196)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics.
Study: NCT05407597
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics.
Study: NCT05659992
Drug: azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)
Study: NCT04929236
Drug: Panzyga
Normalized name: Panzyga
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
Study: NCT06012760
Drug: Iron sucrose, Human Erythropoietin Injection, Vitamin C
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants were administered a combined iron supplementation regimen consisting of iron sucrose,Human Erythropoietin Injection, and vitamin C, three times throughout the preoperative week.
Study: NCT05785741
Drug: DB-1310
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered I.V.
Study: NCT05785741
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered I.V.
Study: NCT05785741
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT06354985
Drug: Modafinil 200mg
Normalized name: MODAFINIL 200MG TAB
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 200mg daily for 8 weeks.
Study: NCT05027672
Drug: Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)
DrugBank: Gam-COVID-Vac (DB15848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
Study: NCT05866627
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05866627
Drug: Afimetoran
Normalized name: Afimetoran
DrugBank: Afimetoran (DB16580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06185660
Drug: sodium zirconium cyclosilicate (SZC)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
Study: NCT06534437
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Study: NCT05490680
Drug: Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
Study: NCT05799183
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment SHR-1210 before process changes 20 mg
Study: NCT05799183
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment SHR-1210 after process changes 20 mg
Study: NCT04398316
Drug: Lidocaine Iv
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg over 5 minutes
Study: NCT04398316
Drug: HYDROmorphone Injection
Normalized name: hydromorphone Injection
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg over 5 minutes
Study: NCT05685836
Drug: Bevacizumab Zirconium Zr-89
Normalized name: Bevacizumab zirconium Zr-89
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description.
Study: NCT06364072
Drug: CT001
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal
Study: NCT05512208
Drug: Avutometinib (VS-6766) + defactinib
Normalized name: Avutometinib
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle.